Low-Dose Naltrexone and Rosuvastatin Interaction

Why This Combination Comes Up

Patients using rosuvastatin for dyslipidemia increasingly ask about adding low-dose naltrexone for chronic pain, autoimmune conditions, or systemic inflammation. LDN has gained traction in off-label use for fibromyalgia, Crohn's disease, and multiple sclerosis at doses far below the 50 mg FDA-approved naltrexone dose for opioid use disorder. Rosuvastatin (brand name Crestor) remains one of the most prescribed statins worldwide, with over 28 million U.S. Prescriptions dispensed annually according to ClinCalc drug usage statistics. The overlap in patient populations, particularly those managing metabolic syndrome alongside chronic inflammatory conditions, makes this a practical question.

Who Typically Takes Both

The typical patient profile includes adults aged 40 to 65 managing hyperlipidemia with a statin while exploring LDN for fibromyalgia, Hashimoto's thyroiditis, or other autoimmune-mediated inflammation. A 2022 survey published in Clinical Rheumatology estimated that 5% to 10% of fibromyalgia patients in specialty clinics had tried LDN within the prior 12 months [1]. Many of these patients carry concurrent cardiovascular risk factors requiring statin therapy.

Why Patients Worry

The naltrexone FDA label for the 50 mg formulation carries a boxed warning about hepatotoxicity at higher doses [2]. Statins, including rosuvastatin, also carry hepatotoxicity warnings in their prescribing information [3]. Patients understandably wonder whether combining two drugs with liver safety signals compounds that risk.

Pharmacokinetic Mechanisms: How Each Drug Is Processed

Understanding whether two drugs interact requires mapping their metabolic pathways. LDN and rosuvastatin travel through largely separate enzymatic and transporter systems.

Naltrexone Metabolism at Low Doses

Naltrexone undergoes extensive first-pass hepatic metabolism. The primary route is reduction by dihydrodiol dehydrogenase to its active metabolite 6-beta-naltrexol, with secondary oxidative metabolism via CYP3A4 [2]. At the standard 50 mg dose, naltrexone produces peak plasma concentrations of roughly 8.6 ng/mL. At LDN doses (1.5 to 4.5 mg), plasma levels are proportionally lower, roughly 30- to 10-fold below the approved dose, making clinically significant enzyme inhibition or induction extremely unlikely. Naltrexone is not a known inhibitor or inducer of CYP2C9, CYP2C19, or the OATP transporters.

Rosuvastatin Metabolism and Transport

Rosuvastatin is distinct among statins because it undergoes minimal CYP-mediated metabolism. Approximately 10% is metabolized by CYP2C9, with the remainder excreted unchanged through biliary and renal routes [3]. The critical step in rosuvastatin's disposition is its uptake into hepatocytes via OATP1B1 (encoded by SLCO1B1) and OATP1B3 (encoded by SLCO1B3). Drugs that inhibit these transporters, such as cyclosporine, certain protease inhibitors, and gemfibrozil, can dramatically raise rosuvastatin plasma levels and increase myopathy risk. The FDA label for rosuvastatin specifically lists OATP1B1 inhibitors as a basis for dose restrictions [3].

Naltrexone has no documented activity as an OATP1B1 or OATP1B3 inhibitor. This is the single most important mechanistic point: the transporter pathway that makes rosuvastatin vulnerable to drug interactions is not affected by naltrexone at any studied dose.

P-glycoprotein and BCRP Considerations

Rosuvastatin is also a substrate of breast cancer resistance protein (BCRP/ABCG2). Inhibitors of BCRP can increase rosuvastatin bioavailability. Naltrexone has been studied as a P-gp substrate in preclinical models, but there is no published evidence that it inhibits BCRP at therapeutic or subtherapeutic concentrations [4]. This further supports the absence of a meaningful pharmacokinetic interaction.

Pharmacodynamic Overlap: Shared Organ Effects

Even when two drugs do not interact pharmacokinetically, they can produce additive effects on the same organ system. The liver is the relevant concern here.

Hepatic Safety Signals

The naltrexone 50 mg label warns that hepatocellular injury can occur, though the FDA's own review notes this was observed primarily at doses of 300 mg/day (6 times the approved dose) in early obesity trials [2]. At LDN doses, hepatotoxicity reports are exceedingly rare. A 2020 retrospective in the Journal of Clinical Pharmacy and Therapeutics reviewing LDN use in 215 patients with autoimmune disease found zero cases of ALT elevation exceeding 3 times the upper limit of normal over a median follow-up of 11 months [5].

Rosuvastatin, like all statins, can cause transaminase elevations. The JUPITER trial (N=17,802) documented ALT elevations above 3 times the upper limit of normal in 0.3% of the rosuvastatin 20 mg group versus 0.2% in the placebo group, a difference that was not statistically significant [6]. Serious hepatotoxicity from rosuvastatin monotherapy is rare.

Additive Liver Risk Assessment

Because both drugs individually carry low but nonzero hepatic risk, prudent practice is to check liver function tests (ALT, AST) at baseline before starting the combination, then recheck at 4 to 8 weeks. If both values remain below 2 times the upper limit of normal and the patient is asymptomatic, routine annual monitoring is sufficient. This recommendation aligns with the American College of Cardiology/American Heart Association statin safety monitoring guidance published in 2018 [7].

Myopathy and Muscle Effects

Statin-associated muscle symptoms (SAMS) affect an estimated 7% to 29% of statin users depending on the definition used, according to a 2015 European Heart Journal meta-analysis [8]. The mechanism involves mitochondrial dysfunction in skeletal muscle, potentially mediated by reduced coenzyme Q10 synthesis.

LDN has no known effect on mitochondrial bioenergetics or coenzyme Q10 metabolism. No case reports link LDN to myopathy or rhabdomyolysis. The combination does not create a pharmacological basis for increased muscle toxicity beyond rosuvastatin's baseline risk.

Clinical Risk Rating and DDI Database Review

What the Major Databases Say

A search of Lexicomp, Micromedex, and Clinical Pharmacology databases returns no listed interaction between naltrexone (at any dose) and rosuvastatin. The FDA's Adverse Event Reporting System (FAERS) contains no signal for the combination through Q1 2026. This does not prove safety, as absence of evidence is not evidence of absence, but it does indicate that among the millions of patients prescribed each drug, no pattern of harm from the combination has emerged.

Severity Classification

Using the standard DDI severity framework:

• Pharmacokinetic interaction: None identified. No shared CYP enzymes, no OATP or BCRP inhibition by naltrexone.
• Pharmacodynamic interaction: Theoretical additive hepatic stress, clinically negligible at LDN doses based on available data.
• Overall rating: Low severity. No contraindication. No dose adjustment required.

Monitoring Protocol for Patients on Both Drugs

Even with a low-risk interaction profile, structured monitoring prevents surprises.

Baseline Labs Before Starting LDN

Before adding LDN to an existing rosuvastatin regimen, obtain:

• ALT and AST: Establishes hepatic baseline. If already elevated above 2 times the upper limit of normal, investigate the cause before adding LDN.
• CK (creatine kinase): Confirms no pre-existing myopathy that could confuse later symptom attribution.
• Comprehensive metabolic panel: Documents renal function, which affects rosuvastatin clearance.

Follow-Up Schedule

Recheck ALT and AST at 4 to 8 weeks after starting LDN. If values are stable, return to the standard annual monitoring schedule recommended for statin therapy. CK testing should be symptom-driven rather than routine, meaning it is warranted only if the patient develops new muscle pain, weakness, or dark urine.

Red Flags That Warrant Reassessment

Discontinue LDN and recheck labs promptly if the patient develops:

• Unexplained right upper quadrant pain or jaundice
• ALT or AST rising above 3 times the upper limit of normal on follow-up
• New-onset diffuse myalgias with CK above 5 times the upper limit of normal

These thresholds are consistent with the FDA's rosuvastatin prescribing information safety monitoring recommendations [3].

Dose-Adjustment Guidance

No dose adjustment of either drug is required when combining LDN (1.5 to 4.5 mg daily) with rosuvastatin at any approved dose (5 to 40 mg daily). This stands in contrast to rosuvastatin combinations that do require dose caps. For example, the FDA mandates a maximum rosuvastatin dose of 5 mg daily when co-administered with cyclosporine, and 10 mg daily when combined with lopinavir/ritonavir [3].

Special Populations

Renal impairment (eGFR <30 mL/min/1.73m²): Rosuvastatin starting dose should be 5 mg, with a maximum of 10 mg. LDN does not alter this recommendation because it does not affect rosuvastatin renal clearance.

SLCO1B1 poor metabolizers: Patients carrying the SLCO1B1 521T>C variant (rs4149056) have reduced OATP1B1 function and higher rosuvastatin plasma levels. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline recommends prescribing a lower rosuvastatin dose or an alternative statin for these patients [9]. LDN does not modify this genotype-based recommendation.

Hepatic impairment (Child-Pugh B or C): Rosuvastatin is contraindicated in active liver disease. LDN should also be avoided in significant hepatic impairment because naltrexone clearance depends on hepatic metabolism [2].

What About Full-Dose Naltrexone (50 mg)?

The interaction profile changes modestly at the standard 50 mg naltrexone dose used for opioid or alcohol use disorder. The hepatotoxicity risk is higher at 50 mg, and the additive hepatic pharmacodynamic concern becomes more clinically relevant. A 2014 VA study of 89,000 veterans on naltrexone 50 mg found an adjusted odds ratio of 1.34 (95% CI 1.11 to 1.62) for ALT elevations above 5 times the upper limit of normal compared to matched controls not receiving naltrexone [10]. When combining full-dose naltrexone with a statin, more frequent LFT monitoring (every 1 to 3 months for the first year) is reasonable.

At LDN doses, this concern is substantially attenuated. The dose-response relationship for naltrexone hepatotoxicity is steep, and doses below 4.5 mg have not produced a detectable hepatic signal in any published cohort.

Patient Counseling Points

Prescribers and pharmacists should communicate the following to patients starting both medications:

Timing: LDN is typically taken at bedtime to align with the nocturnal endorphin surge, while rosuvastatin can be taken at any time of day. There is no need to separate doses by a specific interval because there is no absorption interaction.

Alcohol: Both drugs individually warrant caution with heavy alcohol use. Naltrexone's hepatic warning is amplified by concurrent alcohol exposure. Rosuvastatin myopathy risk may increase with alcohol-related nutritional deficiencies. Patients should limit alcohol to moderate intake (1 drink daily for women, 2 for men) per AHA guidelines [11].

Symptom reporting: Patients should report unexplained muscle pain, dark-colored urine, unusual fatigue, or yellowing of the skin or eyes. These symptoms may or may not be drug-related but require prompt evaluation.

Opioid caution: Naltrexone, even at low doses, blocks opioid receptors. Patients must inform emergency providers and anesthesiologists that they are taking naltrexone, as it can blunt the effect of opioid analgesics during acute pain management.

The Evidence Gap

No randomized controlled trial has studied LDN combined with rosuvastatin. The safety assessment relies on mechanistic pharmacology, extrapolation from higher-dose naltrexone data, and the absence of adverse signals in post-marketing surveillance. This is typical for off-label compounded medications, where formal DDI studies are rarely funded.

The strongest available evidence comes from the known metabolic pathways of each drug. Dr. Jarred Younger at the University of Alabama at Birmingham, a leading LDN researcher, has noted: "Low-dose naltrexone's pharmacokinetic footprint is small enough that significant drug-drug interactions are unlikely at doses we use clinically" [12]. This aligns with the mechanistic analysis: a drug present at sub-nanomolar concentrations in plasma after a 4.5 mg oral dose is not going to meaningfully inhibit hepatic enzymes or transporters.

Patients starting LDN at 1.5 mg with an 8-week titration to 4.5 mg alongside rosuvastatin 10 to 20 mg should have baseline ALT, AST, and CK checked before initiation, with a single follow-up panel at 6 to 8 weeks.